Page last updated: 2024-10-27

fenofibrate and Cirrhosis

fenofibrate has been researched along with Cirrhosis in 20 studies

Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE

Research Excerpts

ExcerptRelevanceReference
" In the present study, we sought to investigate in greater detail the effect of fenofibrate and its mechanism of action on renal inflammation and tubulointerstitial fibrosis in an animal model of type 2 diabetes mellitus."7.76Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. ( Emmett, N; Li, L; Mann, D; Zhao, X, 2010)
"The PPAR alpha activator fenofibrate prevented development of hypertension, and improved myocardial inflammation and collagen deposition in Ang II-infused rats."7.72PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. ( Amiri, F; Benkirane, K; Cohn, JS; Diep, QN; Endemann, D; Schiffrin, EL, 2004)
"Fenofibrate treatment restored to normal values the ejection and shortening fractions, left ventricular end-diastolic, left ventricular end-systolic diameter, and isovolumic relaxation time."5.46Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease. ( Cevey, ÁC; Donato, M; Gelpi, RJ; Goren, NB; Mirkin, GA; Penas, FN; Rada, MJ, 2017)
" A rat model of renal transplantation was treated with the lipid-lowering drug, fenofibrate, and kidney fibrosis levels were determined by histochemical staining."4.31Targeted changes in blood lipids improves fibrosis in renal allografts. ( Li, G; Liu, B; Meng, Q; Wang, Y; Xu, ZX; Yang, H; Zhang, D; Zhang, YH; Zhou, H, 2023)
" In the present study, we sought to investigate in greater detail the effect of fenofibrate and its mechanism of action on renal inflammation and tubulointerstitial fibrosis in an animal model of type 2 diabetes mellitus."3.76Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. ( Emmett, N; Li, L; Mann, D; Zhao, X, 2010)
"Peroxisome proliferator-activated receptor (PPAR) activation may prevent cardiac hypertrophy and inhibit production of endothelin-1 (ET-1), a hypertrophic agent."3.72Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. ( Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC, 2003)
"The PPAR alpha activator fenofibrate prevented development of hypertension, and improved myocardial inflammation and collagen deposition in Ang II-infused rats."3.72PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. ( Amiri, F; Benkirane, K; Cohn, JS; Diep, QN; Endemann, D; Schiffrin, EL, 2004)
" We tested this hypothesis using rat thioacetamide (TAA) models of liver cirrhosis."3.72PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. ( Harano, Y; Itoh, Y; Kirishima, T; Minami, M; Morita, A; Nakamura, H; Okanoue, T; Toyama, T; Yamauchi, N, 2004)
"Fenofibrate treatment restored to normal values the ejection and shortening fractions, left ventricular end-diastolic, left ventricular end-systolic diameter, and isovolumic relaxation time."1.46Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease. ( Cevey, ÁC; Donato, M; Gelpi, RJ; Goren, NB; Mirkin, GA; Penas, FN; Rada, MJ, 2017)
"Fenofibrate was given to db/db mice in combination with anti-flt-1 hexamer and anti-flk-1 heptamer (VEGFR inhibition) for 12 weeks."1.40Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice. ( Chang, YS; Cho, YR; Hong, BY; Kim, HW; Kim, MY; Kim, TW; Kim, YS; Lim, JH; Park, CW, 2014)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (35.00)29.6817
2010's9 (45.00)24.3611
2020's4 (20.00)2.80

Authors

AuthorsStudies
Qiu, Z1
Zhao, Y1
Tao, T1
Guo, W1
Liu, R1
Huang, J1
Xu, G1
Horinouchi, Y1
Murashima, Y1
Yamada, Y1
Yoshioka, S1
Fukushima, K1
Kure, T1
Sasaki, N1
Imanishi, M1
Fujino, H1
Tsuchiya, K1
Shinomiya, K1
Ikeda, Y1
Zhang, YH1
Liu, B1
Meng, Q1
Zhang, D1
Yang, H1
Li, G1
Wang, Y4
Zhou, H2
Xu, ZX1
Nakano, Y1
Arima, T1
Tobita, Y1
Uchiyama, M1
Shimizu, A1
Takahashi, H1
Cheng, L1
Ge, M1
Lan, Z1
Ma, Z1
Chi, W1
Kuang, W1
Sun, K1
Zhao, X2
Liu, Y1
Feng, Y1
Huang, Y1
Luo, M1
Li, L2
Zhang, B1
Hu, X1
Xu, L1
Liu, X1
Huo, Y1
Deng, H1
Yang, J1
Xi, Q1
Zhang, Y2
Siegenthaler, JA1
Chen, L1
Cevey, ÁC1
Mirkin, GA1
Donato, M1
Rada, MJ1
Penas, FN1
Gelpi, RJ1
Goren, NB1
Kim, Y1
Hwang, SD1
Lim, JH2
Kim, MY2
Kim, EN1
Choi, BS1
Kim, YS2
Kim, HW2
Park, CW2
Pang, L1
Lin, J1
Cho, YR1
Kim, TW1
Hong, BY1
Chang, YS1
Weng, H1
Ji, X1
Endo, K1
Iwai, N1
Zhang, J1
Cheng, Y1
Gu, J1
Wang, S1
Zhou, S1
Tan, Y1
Feng, W1
Fu, Y1
Mellen, N1
Cheng, R2
Ma, J1
Zhang, C1
Li, Z1
Cai, L1
Ding, L1
He, X1
Takahashi, Y1
Ma, JX1
Okada, M1
Sano, F1
Ikeda, I1
Sugimoto, J1
Takagi, S1
Sakai, H1
Yanai, T1
Emmett, N1
Mann, D1
Iglarz, M1
Touyz, RM1
Viel, EC1
Paradis, P1
Amiri, F2
Diep, QN2
Schiffrin, EL2
Benkirane, K1
Cohn, JS1
Endemann, D1
Ogata, T1
Miyauchi, T1
Sakai, S1
Takanashi, M1
Irukayama-Tomobe, Y1
Yamaguchi, I1
Toyama, T1
Nakamura, H1
Harano, Y1
Yamauchi, N1
Morita, A1
Kirishima, T1
Minami, M1
Itoh, Y1
Okanoue, T1
Duhaney, TA2
Cui, L2
Rude, MK1
Lebrasseur, NK2
Ngoy, S1
De Silva, DS2
Siwik, DA1
Liao, R1
Sam, F2
Ip, PC1
Joseph, L1

Other Studies

20 other studies available for fenofibrate and Cirrhosis

ArticleYear
Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy.
    Cells, 2022, 10-11, Volume: 11, Issue:20

    Topics: Animals; Arrhythmogenic Right Ventricular Dysplasia; Biomarkers; Collagen Type I; Desmoglein 2; Dise

2022
Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.
    Life sciences, 2023, May-15, Volume: 321

    Topics: Animals; Creatinine; Fenofibrate; Fibrosis; Kidney; Mice; PPAR alpha; Renal Insufficiency, Chronic;

2023
Targeted changes in blood lipids improves fibrosis in renal allografts.
    Lipids in health and disease, 2023, Dec-04, Volume: 22, Issue:1

    Topics: Allografts; Animals; Cholesterol; Fatty Acids, Omega-3; Fenofibrate; Fibrosis; Humans; Hyperlipidemi

2023
Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model.
    International journal of molecular sciences, 2020, Jul-19, Volume: 21, Issue:14

    Topics: Animals; Burns, Chemical; Corneal Injuries; Corneal Neovascularization; Cytokines; Disease Models, A

2020
Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity.
    Archives of toxicology, 2018, Volume: 92, Issue:1

    Topics: Animals; Benzamides; Cell Line; Coenzyme A Ligases; Dioxoles; Epithelial Cells; Fatty Acids; Fenofib

2018
Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease.
    International journal for parasitology. Drugs and drug resistance, 2017, Volume: 7, Issue:3

    Topics: Animals; Chagas Cardiomyopathy; Chagas Disease; Diastole; Fenofibrate; Fibrosis; Humans; Inflammatio

2017
Attenuated Lymphatic Proliferation Ameliorates Diabetic Nephropathy and High-Fat Diet-Induced Renal Lipotoxicity.
    Scientific reports, 2019, 02-13, Volume: 9, Issue:1

    Topics: Acute Kidney Injury; AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line; Cell Proliferatio

2019
Fenofibrate Improved Interstitial Fibrosis of Renal Allograft through Inhibited Epithelial-Mesenchymal Transition Induced by Oxidative Stress.
    Oxidative medicine and cellular longevity, 2019, Volume: 2019

    Topics: Animals; Cell Line; Epithelial Cells; Epithelial-Mesenchymal Transition; Fenofibrate; Fibrosis; Hydr

2019
Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Blood

2014
Pex11a deficiency is associated with a reduced abundance of functional peroxisomes and aggravated renal interstitial lesions.
    Hypertension (Dallas, Tex. : 1979), 2014, Volume: 64, Issue:5

    Topics: Animals; Disease Models, Animal; Fatty Acids; Female; Fenofibrate; Fibrosis; Hypertension; Hypolipid

2014
Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice.
    Clinical science (London, England : 1979), 2016, Volume: 130, Issue:8

    Topics: Animals; Autophagy; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty

2016
Interaction of PPARα With the Canonic Wnt Pathway in the Regulation of Renal Fibrosis.
    Diabetes, 2016, Volume: 65, Issue:12

    Topics: Animals; beta Catenin; Blotting, Western; Cells, Cultured; Diabetic Nephropathies; Fenofibrate; Fibr

2016
Fenofibrate-induced muscular toxicity is associated with a metabolic shift limited to type-1 muscles in rats.
    Toxicologic pathology, 2009, Volume: 37, Issue:4

    Topics: Animals; Data Interpretation, Statistical; Fenofibrate; Fibrosis; Gene Expression; Gene Expression P

2009
Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy.
    Experimental biology and medicine (Maywood, N.J.), 2010, Volume: 235, Issue:3

    Topics: Actins; Animals; Collagen; Diabetic Nephropathies; Fenofibrate; Fibrosis; Hypolipidemic Agents; Infl

2010
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
    Hypertension (Dallas, Tex. : 1979), 2003, Volume: 42, Issue:4

    Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; En

2003
PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.
    Journal of molecular and cellular cardiology, 2004, Volume: 36, Issue:2

    Topics: Angiotensin II; Animals; Blood Pressure; Collagen; Electrocardiography; Fenofibrate; Fibrosis; Heart

2004
Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with
    Journal of the American College of Cardiology, 2004, Apr-21, Volume: 43, Issue:8

    Topics: Animals; Blotting, Western; Cardiac Output, Low; Desoxycorticosterone; Diastole; Fenofibrate; Fibros

2004
PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats.
    Biochemical and biophysical research communications, 2004, Nov-12, Volume: 324, Issue:2

    Topics: Animals; Antioxidants; Blotting, Northern; Catalase; Densitometry; Fenofibrate; Fibrosis; Hydrogen P

2004
Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:5

    Topics: Aldosterone; Animals; Cells, Cultured; Chronic Disease; Extracellular Signal-Regulated MAP Kinases;

2007
Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:3

    Topics: Aldosterone; Animals; Blood Pressure; Extracellular Matrix; Fenofibrate; Fibrosis; Heart; Heart Rate

2007